At the American Society of Hematology Annual Meeting last December, bluebird and Celgene provided an extremely encouraging clinical update on bb2121's ongoing dose-escalation study. The two companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback